More importantly, potassium channels show high variability and abnormal expression in many tumor types (Cho et al., 2006; Brevet et al., 2009a; Menéndez et al., 2012), such as breast cancer (Ko et al., 2013), colorectal cancer (Ishaque et al., 2018), prostate cancer (Rose et al., 2018), lung cancer (Zhang et al., 2017), liver cancer (Wang et al., 2017), and glioma (Huang et al., 2015). This evidence concerns the gene KCNA3 and prostate carcinoma.